[chrisamiller]

Part of my research involves designing these cancer vaccines. There are different delivery mechanisms, but the need to synthesize medical-grade peptides or mRNA vaccines is one of the major drivers of cost. The sequencing costs are pretty minimal at this point, but analysis of that data by a team of experts is part of that cost as well. This is still largely bespoke stuff that can't quite be standardized because we're still figuring out the best approaches, but there are quite a lot of people working on it!